SMC基因家族在肝癌中的表达及其预测肝癌预后的临床意义

目的 研究SMC基因家族在肝癌组织中的表达水平,及其与肝癌分期和预后的相关性.方法 应用UALCAN和Human Protein Atlas数据库,分析SMC基因家族在肝癌组织和正常肝组织的表达水平,并进一步分析其在肝癌不同分期中的转录水平.利用GEPIA数据库完成对SMC家族各成员基因与肝癌的生存预后相关性分析.结果...     

Dynamics of the bacterial SMC complex and SMC-like proteins involved in DNA repair

Bacteria and archaea possess several different SMC-like proteins, which perform essential functions in a variety of chromosome dynamics, such as chromosome compaction, segregation, and DNA repair. SMC-like proteins localize to distinct sites within the cells at different time points in the cell cycle, or are recruited to sites of DNA breaks and damage. The bacterial SMC (MukB) complex appears to perform a condensin-like function, while SbcC and RecN act early during DNA repair, but apparently at different sites within the cells. Thus, bacterial SMC-like proteins have dynamic functions in chromosome segregation and maintenance of genetic stability.     

Cerebral capillary endothelial cells are covered by the VEGF-expressing foot processes of astrocytes

Molecules that have crucial functions in both nervous and vascular systems have attracted keen attention recently, and the name "angioneurins" has been proposed. The most striking example of angioneurins is vascular endothelial growth factor A (VEGF), which was originally identified as a key regulator of angiogenesis and has only recently been found to have important functions in the nervous system. In this study, we compared VEGF expression in the vasculature in the brain with that in the aorta and the vasculature in the kidney in mice. In larger vessels containing smooth muscle cells, VEGF was expressed by smooth muscle cells covering the lining of endothelial cells, both in and outside the brain. In cerebral capillaries lacking smooth muscle cells, endothelial cells were closely covered by VEGF-expressing foot processes of astrocytes, whereas capillaries were surrounded by VEGF-expressing processes of podocytes in the renal glomeruli. We also found that cultured cerebral microvessel endothelial cells do not express VEGF, whereas cultured cortical astrocytes do express VEGF.     

抗癌药联合应用复方丹参的初步观察

合用复方丹参与西药经导管灌注治疗晚期癌肿13例,单纯西药化疗30例作对照组。比较两组疗效及毒副反应,研究组与对照组缓解率分别为77％与33％,毒副反应研究组明显低于对照组。结果表明:复方丹参在癌肿治疗中具有扶正祛邪的功效。     

Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF β-receptors

Abstract. The mechanism of diabetic macroangio-pathy was studied from the view point of phenotypic change of aortic smooth muscle cells (SMC). The growth rates of cultured SMC of diabetic rats or rabbits were higher than those of non-diabetic animals (controls). This difference of the growth responses was observed specifically with platelet-derived growth factor (PDGF). Of the three PDGF dimers, PDGF-AB heterodimer (PDGF-AB) and PDGF-BB homodimer (PDGF-BB) stimulated growth of diabetic SMC more than that of control SMC but PDGF-A A homodimer (PDGF-AA) did not. The binding of '²⁵1-PDGF to the diabetic SMC was greater than that to control SMC. This was due to increase in the number of cell surface receptors for PDGF. On in vitro culture, SMC from diabetic rats expressed more PDGF β -receptor mRNA than SMC from non-diabetic rats. Moreover, in vivo , the aortic media of diabetic rabbits expressed PDGF β -receptor mRNA, but that from non-diabetic rabbits did not. Thus diabetic SMC over-react on PDGF stimulation through over-expression of the PDGF P-receptor gene. The significance of this fact in development of diabetic macroangiopathy is discussed.     

索诺玛宝冲剂的药理研究

索诺玛宝冲剂（简称ＳＭＣ）用２．１６，４．３２ｇ／（ｋｇ．ｄ）ｐｏ给小鼠连续３天有抗窒息缺氧作用；用２．１６ｇ／（ｋｇ．ｄ）ｐｏ给小鼠连续４天，有抗减压缺氧作用，用１．１４、２．１６ｇ／（ｋｇ．ｄ）ｐｏ给小鼠连续３天，对结扎小鼠两侧颈动脉引起的脑缺血，缺氧的有保护作用，用２．１６ｇ／（ｋｇ．ｄ）ｉｐ给小鼠，能延长异丙肾上腺素引起的心肌耗氧量增加所致小鼠死亡的存活时间，用２．１６ｇ／（ｋｇ．ｄ）ｐｏ     

Cellular pharmacokinetics and pharmacodynamics of dipyridamole in vascular smooth muscle cells

Hemodialysis arteriovenous grafts are often plagued by stenosis at the vein-graft anastomosis, which is due to the proliferation of venous smooth muscle cells (SMCs). Perivascular delivery of dipyridamole, a potent antiproliferative agent, has been proposed for the prevention of graft stenosis. In order to develop an optimal delivery system for dipyridamole, we examined its pharmacokinetics and pharmacodynamics in human and porcine venous and arterial SMCs in vitro. SMCs were incubated with dipyridamole for various durations, and visualized for the uptake and release by fluorescence microscopy, which were further quantified by fluorospectrometry. The antiproliferative effect of dipyridamole was examined by cell counting or the methylthiazoletetrazolium (MTT) dye-reduction assay. Cytotoxicity was examined by the lactate dehydrogenase (LDH)-release assay. The kinetics of dipyridamole transport through the cell membrane was compatible with a passive diffusion mechanism. Dipyridamole inhibited SMC proliferation in a dose-dependent manner and was more effective in venous than arterial cells in both species. The inhibition was completely reversible at 15microg/ml upon drug removal from the medium. At 25microg/ml, however, the effect was partially irreversible, which might be attributed to the cytotoxicity of dipyridamole. These data support the need for sustained delivery of dipyridamole to achieve the long-term inhibition of SMC proliferation in the prevention of stenosis since SMCs are continuously stimulated at the anastomosis of hemodialysis arteriovenous grafts.